Dr. Stadler on Approved and Investigational Therapies in RCC
October 2nd 2018Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).
Dr. Stadler on Sequencing Therapies in Prostate Cancer
September 22nd 2018Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.
Dr. Smith Advises Clinicians on Diagnosing Double-Hit and Triplet-Hit Lymphoma
September 6th 2018Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.
Dr. Vokes Discusses Patient Characteristics and Immunotherapy in NSCLC
August 1st 2018Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses patient characteristics when considering immunotherapy in stage III non-small cell lung cancer.
Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer
March 1st 2018Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.
Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma
December 21st 2017Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
Dr. Turaga on Surgery Versus Immunotherapy in Melanoma
March 30th 2017Kiran K. Turaga, MD, associate professor of surgery, vice chief, section of general surgery and surgical oncology, director of the Surgical GI Cancer Program and the Regional Therapeutics Program at The University of Chicago Medicine, discusses whether patients vie for immunotherapy versus surgery as treatment for their melanoma.